−2.16USD
−126.22 MUSD
32.64 M
About Nuvalent, Inc.
Sector
Industry
CEO
James R. Porter
Website
Headquarters
Cambridge
Employees (FY)
92
Founded
2017
ISIN
US6707031075
FIGI
BBG00Z1SLMK5
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of NUVL is 65.14 USD — it has decreased by 0.21% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Nuvalent, Inc. stocks are traded under the ticker NUVL.
Nuvalent, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Nuvalent, Inc. has a max estimate of 110.00 USD and a min estimate of 95.00 USD.
NUVL earnings for the last quarter are −0.59 USD whereas the estimation was −0.58 USD which accounts for −2.02% surprise. Estimated earnings for the next quarter are −0.60 USD. See more details about Nuvalent, Inc. earnings.
Yes, you can track Nuvalent, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, NUVL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Nuvalent, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 92.00 employees. See our rating of the largest employees — is Nuvalent, Inc. on this list?